Leerink Partnrs Comments on PureTech Health FY2025 Earnings

PureTech Health plc (NASDAQ:PRTC - Free Report) - Investment analysts at Leerink Partnrs lifted their FY2025 earnings per share estimates for PureTech Health in a research report issued to clients and investors on Wednesday, April 30th. Leerink Partnrs analyst F. Khurshid now forecasts that the company will post earnings of ($4.28) per share for the year, up from their previous forecast of ($4.84). The consensus estimate for PureTech Health's current full-year earnings is ($4.34) per share. Leerink Partnrs also issued estimates for PureTech Health's FY2026 earnings at ($4.37) EPS.

PureTech Health Price Performance

NASDAQ PRTC traded down $0.51 during trading on Monday, hitting $17.33. 489 shares of the company's stock traded hands, compared to its average volume of 4,664. PureTech Health has a 12-month low of $13.30 and a 12-month high of $32.98. The business has a 50 day moving average of $17.37 and a 200-day moving average of $19.05.

Institutional Trading of PureTech Health

An institutional investor recently bought a new position in PureTech Health stock. Millennium Management LLC purchased a new stake in shares of PureTech Health plc (NASDAQ:PRTC - Free Report) in the fourth quarter, according to the company in its most recent filing with the SEC. The firm purchased 45,264 shares of the company's stock, valued at approximately $823,000. Millennium Management LLC owned about 0.19% of PureTech Health at the end of the most recent quarter. 0.04% of the stock is owned by institutional investors and hedge funds.

About PureTech Health

PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies.